Simile Raises $200 Million for Consumer AI Twins
Simile raised $200 million at a $2 billion valuation on July 30, 2026, to build AI-generated "agentic twins" for market research. The New York Times reports that Greenoaks led the round, with Index Ventures, Hanabi, A*, Bain Capital Ventures, CVS Health Ventures and Definition participating; Simile lists CVS Health, Deloitte and Wealthfront as clients.
Simile raised $200 million at a $2 billion valuation on July 30, 2026, to develop AI-generated consumer stand-ins, known as "agentic twins," for market-research use. The New York Times reports that Greenoaks led the financing, with existing investors Index Ventures, Hanabi, A*, Bain Capital Ventures, CVS Health Ventures and Definition participating.
The Palo Alto startup, founded last year by Stanford computer science Ph.D. candidate Joon Sung Park, provides companies with simulated panels intended to test product reactions, brand perception and behavioral interventions. According to the New York Times, CVS Health used data from 400,000 agentic twins last fall to examine ways to improve prescription adherence. Deloitte and Wealthfront are also clients, according to the Times and The Next Web.
"If you're able to simulate the world, you can basically test out countless interventions," Park told the New York Times. "This is sort of the window into humanity."
How Simile builds its panels
The Next Web reports that Simile conducted two-hour interviews with 1,000 representative participants and worked with Gallup to incorporate input from several million additional people. It also reports that the company claims accuracy between 85% and 99%, depending on the group being modeled. Those figures are Simile's own claims, and The Next Web notes that the underlying premise remains contested.
Simile's work draws on a 2023 Stanford paper co-authored by Park on AI agents simulating human behavior in interactive environments. Percy Liang, who helped coin the term "foundation model," is among Simile's co-founders, according to The Next Web.
The financing follows a $100 million round raised less than six months earlier, according to the New York Times. The fresh capital and valuation place simulated respondent systems among a growing set of AI products seeking to replace or augment data collection, research operations and decision testing.
For data science teams, the central technical question is not panel size alone but external validity: whether a model trained on interviews, survey data and behavioral inputs continues to predict outcomes across populations, contexts and changing consumer preferences. Companies deploying comparable systems typically need reproducible validation against held-out human research, subgroup-level error reporting, and controls against synthetic-data feedback loops before treating model outputs as decision-grade evidence.
Key Points
- 1Simile raised $200 million at a $2 billion valuation, underscoring investor demand for AI systems that automate consumer research workflows.
- 2CVS Health used 400,000 simulated respondents, illustrating the scale advantage promised by agent-based panels over conventional surveys.
- 3Comparable synthetic-research systems require rigorous external validation because high aggregate accuracy can conceal subgroup errors and changing real-world behavior.
Scoring Rationale
The $200 million round and $2 billion valuation make Simile a notable AI funding event in the emerging synthetic-market-research category. The product's claimed predictive performance could matter for applied ML teams, but the reported accuracy figures remain company claims and the approach is contested.
Sources
Public references used for this report.
Practice interview problems based on real data
1,625 SQL & Python problems across 15 industry datasets — the exact type of data you work with.
Try 250 free problems
